期刊文献+

84例骨髓增生异常综合征细胞遗传学特点及预后评估分析 被引量:3

Cytogenetic features and prognosis analysis in eighty-four Chinese patients with myelodysplastic syndromes
原文传递
导出
摘要 目的:分析中国人种骨髓增生异常综合征(MDS)患者的骨髓细胞染色体异常特点,探讨细胞遗传学检测在我国MDS诊断及预后评估中的应用价值。方法:采用染色体核型分析结合荧光原位杂交(FISH)技术,检测84例MDS确诊病例的骨髓细胞染色体异常,将患者的骨髓细胞遗传学结合临床特点进行综合分析。结果:84例MDS患者中,存在骨髓细胞染色体异常者38例,占45.2%,其中+8、-7/7q-和20q-最常见,无单纯5q-者。具有预后良好染色体者55例,具有预后中等染色体者14例,具有预后不良染色体者15例。16例三系病态造血患者中染色体异常者10例(62.5%),其余68例患者中染色体异常者28例(41.2%),三系病态造血患者中染色体异常者比例似乎较高,但差异无统计学意义(P>0.05)。经随访6~24个月,84例患者中已死亡29例。预后良好染色体组患者的生存时间高于预后不良染色体组(P<0.01)。结论:中国人种MDS患者中,+8、-7/7q-和20q-为常见的染色体异常,单纯5q-罕见。细胞遗传学分析不仅应作为中国人种MDS诊断的重要依据,同时也是不可替代的预后评估指标。 Objective: To analyze the cytogenetic features of Chinese patiens with myelodysplastic syndromes (MDS) and explore the value of cytogenetic analysis for the diagnosis and prognostic stratification in Chinese MDS patients. Method: Karyotyping and fluorescent in situ hybridization (FISH) analysis were performed in 84 MDS patients. Their cytogenetic features in correlation with clinical manifestations were analyzed. Result: Among the eighty-four patients, thirty-eight (45.2 % ) showed cytogenetic abnormalities. Incidence of trisomy 8,-7/7q- and 20q-- were common but no sole 5q-- was found. Fifty-five patients showed good karyotypes, fourteen patients showed intermediate karyotypes,and fifteen patients showed poor karyotypes. Ten of sixteen patients with trilincage dysplasia(62.5 % ) showed cytogenetie abnormalities, while twenty-eight of the else sixty eight patients (41. 2 ) showed cytogenetic abnormalities. The proportion of patients with abnormal karyotypes seemed higher in the patients with trilineage dysplasia than that in other patients, but the difference was not statistically significant (P〉0.05). During the follow up belween six months and twenty-four months, twenty-nine patients died. The survival time of the good karyotypic group was longer than that of poor karyotypic group (P〈0.01). Conclusion:Occurrence of trisomy 8,--7/7q and 20q-- was common but sole 5q-- was rare in Chinese MDS patients. Cytogenetic feature is not only indispensable for diagnosis, but also an independent prognostic factor in Chinese MDS patients.
出处 《临床血液学杂志》 CAS 2013年第3期315-318,共4页 Journal of Clinical Hematology
基金 国家自然科学基金项目(No:81100360) 中华医学会分子生物学应用研究专项资金(No:CAMB042010) 卫生部临床重点建设专科建设项目
关键词 骨髓增生异常综合征 诊断 预后 细胞遗传学分析 myelodysplastic syndromes diagnosis prognosis cytogenetic analysis
  • 相关文献

参考文献14

  • 1VARD1MAN J W, THIELE J , ARBER D A,et al.The 2008 revision of the World Health Organization(WHO) classification of myeloid neoplasms and acuteleukemia: rationale and important changes[J]. Blood,2009,114:937—951.
  • 2GREENBERG P,COX C,LEBEAU M M,et al. Inter-national scoring system for evaluating prognosis inmyelodysplastic syndromes [J]. Blood,1997,89 : 2079—2088.
  • 3VALENT P, HORNY H P, BENNETT J M,et al.Definitions and standards in the diagnosis and treat-ment of the myelodysplastic syndromes : Convsensusstatements and report from a working conference[J],Leuk Res,2007,31:727 — 736.
  • 4BARZI A,SEKERES M A. Myelodysplastic syn-dromes :a practical approach to diagnosis and treat-ment[J]. Cleve Clin J Med,2010,77 :37 —344.
  • 5HAASE D,GERMING U,SCHANZ J,et al. New in-sights into the prognostic impact of the karyotype inMDS and correlation with subtypes: evidence from acore dataset of 2 124 patients [J]. Blood, 2007 , 110 :4385-4395.
  • 6HAASE D. Cytogenetic features in myelodysplasticsyndromes[J]. Ann Hematol ,2008,87 ; 515 — 526.
  • 7WANG H, WANG X, XU X, et al. Cytogenetic fea-tures and prognosis analysis in Chinese patients withmyelodysplastic syndrome: a multicenter study [ J ].Ann Hematol,2010,89 : 535 — 544.
  • 8曲士强,刘旭平,徐泽锋,张悦,秦铁军,张天佼,崔蕊,郝玉书,肖志坚.不同细胞遗传学预后分组对原发性骨髓增生异常综合征患者预后意义的研究[J].中华血液学杂志,2011,32(12):819-824. 被引量:13
  • 9AFABLE M G 2nd,TIU R V, MACIEJEWSK1 J P.Clonal evolution in aplastic anemia [J]. HematologyAm Soc Hematol Educ Program.2011,2011:90 — 95.
  • 10MA Y,WANG X,XU X,et al. Prognostic value of tri-somy 8 in primary myelodysplastic syndrome[J]. In-tern Med J,2010,40:697-703.

二级参考文献12

  • 1Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood, 1997, 89:2079-2088.
  • 2Haase D, Germing U, Schanz J, et al. New insights into the prog- nostic impact of the karyotype in MDS and correlation with sub- types: evidence from a core dataset of 2124 patients. Blood, 2007, 110: 4385-4395.
  • 3Schanz J, Tuchler H, Sole F, et al. Proposal of a new, compre- hensive cytogenetic scoring system for primary MDS. Haematologi- ca, 2010, 95 Suppl 2: Abstract 535.
  • 4Greenberg P, Tuechler H, Schanz J, et al. Revised International Prognostic Scoring System ( IPSS-R), developed by the Interna- tional Prognostic Working Group for Prognosis in MDS ( IWG- PM). Leuk Res, 2011, 35 Suppl 1: Abstract 14.
  • 5Chun K, Hagemeijer A, Iqbal A, et al. Implementation of stand- ardized international karyotype scoring practices is needed to pro- vide uniform and systematic evaluation for patients with myelodys- plastic syndrome using IPSS criteria: An International Working Group on MDS Cytogenetics Study. Leuk Res, 2010, 34: 160- 165.
  • 6Valent P, Horny HP, Bennett JM, et al. Definitions and standards in the diagnosis and treatment of the rnyelodysplastic syndromes: Consensus statements and report from a working conference. Leuk Res, 2007, 31 : 727-736.
  • 7Haase D. Cytogenetic features in myelodysplastic syndromes. Ann Hematol, 2008, 87: 515-526.
  • 8Schanz J, Steidl C, Fonatsch C, et al. Coalesced muhicentric analysis of 2,351 patients with myelodysplastic syndromes indi- cates an underestimation of poor-risk cytogenetics of myelodysplas- tic syndromes in the International Prognostic Scoring System. J Clin Oncol, 2011,29 : 1963-1970.
  • 9Sole F, Luno E, Sanzo C, et al. Identification of novel cytogenetic markers with prognostic significance in a series of 968 patients with primary myelodysplastic syndromes. Haematologica, 2005, 90: 1168-1178.
  • 10Bernasconi P, Klersy C, Boni M, et al. World Health Organiza- tion classification in combination with cytogenetic markers im- proves the prognostic stratification of patients with de novo prima- ry myelodysplastic syndromes. Br J Haematol, 2007, 137: 193- 205.

共引文献12

同被引文献25

  • 1邱镜滢,赖悦云,柴晔,张艳,师岩,何琦,党辉,陆道培.306例骨髓增生异常综合征染色体核型的研究[J].中国实验血液学杂志,2004,12(4):455-459. 被引量:32
  • 2于明华,刘世和,邵英起,郝玉书,肖志坚.原发性骨髓增生异常综合征患者染色体核型与IPSS危度分组:FAB与WHO分型比较[J].中华血液学杂志,2004,25(8):482-485. 被引量:12
  • 3潘含章,陈志妹,楼基余,徐伟来,金洁.283例骨髓增生异常综合征染色体核型分析[J].浙江大学学报(医学版),2006,35(2):143-146. 被引量:8
  • 4王小钦,林果为.282例原发性骨髓增生异常综合征诊断和分型的前瞻性临床研究[J].中华血液学杂志,2006,27(8):546-549. 被引量:34
  • 5Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes [J]. Blood, 1997, 89(6):2079-2088.
  • 6Malcovati L, Germing U, Kuendgen A, et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes[J]. J Clin Oncol, 2007, 25(23):3503-3510.
  • 7Malcovati L, Della Porta MG, Strupp C, et al. Impact of the de- gree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based Prognostic Scoring System (WPSS)[J]. Haematologica, 2011, 96( 10):1433-1440.
  • 8Greenberg PL, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes [ J]. Blood, 2012, 120( 12):2454-2465.
  • 9Vardiman J. The classification of MDS: from FAB to WHO and beyond[ J]. Leuk Res, 2012, 36( 12):1453-1458.
  • 10Kantarjian H, O' Brien S, Ravandi F, et al. Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System[J]. Cancer, 2008, 113(6):1351-1361.

引证文献3

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部